Matthew Hardwick, PhD

Matthew Hardwick, PhD is Co-Founder and Chief Executive Officer of ResInnova Clinical Diagnostics. Dr. Hardwick is a thought leader in the field of infection prevention in the healthcare environment of care and is an expert in antimicrobial surface technologies. He has 20 years of academic research experience, at Georgetown University where he completed his PhD in Cell Biology, and at Johns Hopkins University, where he completed 2 postdoctoral fellowships, one in the Bloomberg School of Public Health and the second in the James Buchanan Brady Urological Institute. Dr. Hardwick’s last academic appointment was with the MedStar Health Research Institute where he worked on numerous research initiatives including the use of antimicrobial surfaces in clinical healthcare environments. He is widely published, including several articles on the use of antimicrobials in clinical environments and the role of microbial surface contamination on infection rates in clinical settings. Dr. Hardwick is also founder and CEO of ResInnova Laboratories, a Maryland-based microbiology laboratory with clients from all over the world. Working closely with community-oriented non-profits, he also serves as an active leader focusing on local partnerships and engagement.

Mary Beth Minyard, MSCLS, M(ASCP)

Mary Beth Minyard, MSCLS, M(ASCP) is Co-Founder and Chief Science Officer of ResInnova Clinical Diagnostics. A board-certified Microbiologist with over 20 years of experience in clinical and applied infectious disease testing, Mary Beth also serves as Principal Consultant to multiple clinical labs and biotech companies and serves on the CLSI Document Development Committee for establishing molecular testing in clinical environments. She has served as Director of Laboratory Operations and Technical Supervisor for a molecular diagnostics laboratory which became one the of the first private labs in the U.S. to provide SARS-CoV-2 (COVID-19) testing. She went on to start COVID-19 programs for both environmental surface testing and pooled surveillance and recently published on the predictors of non-seroconversion after SARS-CoV-2 infection. Mary Beth earned her Bachelor of Science in Microbiology from the University of Georgia and her Master of Science in Clinical Laboratory Sciences from the University of Alabama at Birmingham (UAB) specializing in Microbiology and Immunology.